Ubrelvy (ubrogepant) / Merck (MSD), AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ubrelvy (ubrogepant) / AbbVie
NCT01657370: A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Completed
2b
195
US
MK-1602, Placebo, Rescue medication
Allergan
Migraine
11/12
12/12
NCT01613248: A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

Completed
2b
834
NA
MK-1602, Placebo-matching MK-1602, Rescue medication
Allergan
Migraine
12/12
12/12
NCT05895500: Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

Completed
2a
103
US
Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral
Nvision Laser Eye Centers
Dry Eye, Asthenopia
11/23
11/23

Download Options